Direct Healthcare Professional Communication (DHPC) on Nulojix® (belatacept): Risk of medication errors due to change in maintenance dose from 5 mg/kg to 6 mg/kg
2022.10.04
Active substance: Belatacept
Bristol Myers Squibb in agreement with the European Medicines Agency and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that With the implementation of a new manufacturing process, the maintenance dose for Nulojix® (belatacept) will be changed to 6 mg/kg every 4 weeks. For approximately one to two months starting in the middle of October, Nulojix from both the previous and the new manufacturing processes will coexist on the market.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN